Keylika
YC S22San Francisco, US · Founded 2022 · 1 employees · 1 known investors
Find your way into Keylika
813 people in our graph share verified history with the Keylika team — schools, employers, funds. One of them is your warm intro.
Paul Kwanunlockedknows Buddha Chaudhuri · together at Stanford University (overlapped)
knows the team · via Nanyang Technological University Singapore
×3knows the team · via kuleuven
×2knows the team · via University of California, San Francisco
knows the team · via KU Leuven / IMEC, Belgium
×2knows the team · via Stanford University
Keylika develops a platform synthesis technology for mixed ligand metal complexes to generate organometallic drugs for treating therapeutic conditions including hematology, pain, inflammation, metabolic disorders, infectious diseases, and oncology. The company combines drug development with drug delivery technologies, customizing molecular structure and formulation to optimize clinical outcomes for women, children, elderly, and patients with specific diseases.
BiotechHealthtechMedical DevicesAI-powered Drug DiscoveryDrug DeliveryNanotechnologyTherapeuticsUnited States of AmericaAmerica / CanadaPartly Remote
Founders & leadership· Y Combinator alumni (S22)
Keylika was founded in 2022 by Buddha Chaudhuri, Frederik Ceyssens, Buddhadev P. Chaudhuri, PhD, and Frederik Ceyssens, PhD.
BC
Buddha Chaudhuriin𝕏CEO & Co-FounderBuddha Chaudhuri led technology development for a microneedle biosensor at a Series B medtech company and has spent 15 years developing healthcare technologies across research institutes and biotech firms. He holds a PhD in Drug Delivery Microsystems from KU Leuven/Imec and completed a postdoctoral fellowship at UCSF/UC Berkeley.
FC
Frederik CeyssensinCo-founder · CTOFrederik Ceyssens holds a PhD and Masters in IC design along with a Bachelor's in Medicine, and has spent 15 years developing microtechnologies for life science applications before founding Keylika, a neurotech venture focused on vision restoration.
BP
Buddhadev P. Chaudhuri, PhDin𝕏CEO & Co-FounderBuddhadev P. Chaudhuri holds a PhD in Electrical Engineering from KU Leuven/IMEC focused on transdermal drug delivery via microneedles, and has held research and leadership roles in device microfabrication and process development at biomedical startups including Biolinq (wearable glucose monitoring) and Koniku (synthetic biology/neurotech), as well as postdoctoral positions at UCSF and the University of Leuven. He is the CEO and co-founder of Keylika, which develops organometallic drugs and drug delivery technologies for hematology, pain, inflammation, and other therapeutic conditions.
FC
Frederik Ceyssens, PhDCTO & Co-Founder
Investors · 1
The YC application· Summer 2022 batch
What they told YC
- Describe what your company does in 50 characters or less.
- The company develops metallodrugs aimed at unmet medical needs.
Summarized from the founders' answers on their Y Combinator profile.
In the news
Frequently asked questions
- What does Keylika do?
- Keylika develops a platform synthesis technology for mixed ligand metal complexes to generate organometallic drugs for treating therapeutic conditions including hematology, pain, inflammation, metabolic disorders, infectious diseases, and oncology. The company combines drug development with drug delivery technologies, customizing molecular structure and formulation to optimize clinical outcomes for women, children, elderly, and patients with specific diseases.
- Who founded Keylika?
- Keylika was founded by Buddha Chaudhuri, Frederik Ceyssens, Buddhadev P. Chaudhuri, PhD, Frederik Ceyssens, PhD in 2022.
- Who are Keylika's investors?
- Keylika's investors include Y Combinator.
- Where is Keylika headquartered?
- Keylika is headquartered in San Francisco, US.